查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1546243

現實世界證據解決方案的全球市場

Real World Evidence Solutions
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 246 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球真實證據解決方案市場預計將達到 44 億美元

現實世界證據解決方案的全球市場預計 2023 年為 17 億美元，預計到 2030 年將達到 44 億美元，2023 年至 2030 年複合年成長率為 14.3%。真實世界證據服務是本報告分析的細分市場之一，預計複合年成長率為 15.5%，到分析期結束時將達到 29 億美元。在分析期間，現實世界證據資料集領域的複合年成長率預計為 12.1%。

美國市場預估為4.609億美元，中國預期複合年成長率為13.3%

到 2023 年，美國現實世界證據解決方案市場預計將達到 4.609 億美元。中國作為全球第二大經濟體，預計2030年市場規模將達6.526億美元，2023-2030年分析期間複合年成長率為13.3%。其他值得注意的區域市場包括日本和加拿大，預計在分析期間複合年成長率分別為 12.9% 和 12.0%。在歐洲，德國預計複合年成長率為 10.1%。

全球真實世界證據解決方案市場 - 主要趨勢與促進因素摘要

真實世界證據解決方案：透過資料驅動的見解改變醫療保健

真實世界證據 (RWE) 解決方案正在透過提供資料主導的見解來改變醫療保健，從而增強跨行業的決策。 RWE 是透過真實世界資料(RWD) 分析得出的有關藥物使用以及潛在益處或風險的臨床證據。這些資料是從各種資訊來源收集的，包括電子健康記錄(EHR)、申請資料庫、病患登記和穿戴式裝置。 RWE 擴大被製藥公司、監管機構和醫療保健提供者用來為藥物開發、監管核准和患者護理策略提供資訊。與在受控條件下進行的傳統臨床試驗不同，RWE 可以深入了解治療在常規臨床實踐中的表現，從而更全面地了解產品的功效和安全性。這種方法對於展示新治療方法的價值至關重要，特別是在個人化醫療和罕見疾病方面。

哪些技術進步正在增強 RWE 的收集和利用？

技術進步極大地增強了 RWE 的收集、分析和利用，使其成為醫療保健利益相關人員更強大的工具。透過將巨量資料分析、人工智慧 (AI) 和機器學習 (ML) 整合到 RWE 平台中，我們可以處理大量 RWD 並發現無法手動檢測的模式和見解。資料整合技術的進步還可以集中來自不同來源的資料，創建全面的資料集，提供患者結果的整體視圖。此外，自然語言處理 (NLP) 的使用正在改善從醫生筆記和社交媒體等非結構化來源中提取有意義的資料。這些創新不僅提高了 RWE 的品質和準確性，而且使醫療保健決策者更容易獲得和實用。

RWE 在醫療保健領域的主要用途和好處是什麼？

RWE 在醫療保健領域有著廣泛的應用，在改善病患治療效果、提高醫療效率和支持監管決策方面具有顯著優勢。在藥物開發中，RWE 用於補充臨床試驗資料，深入了解藥物在不同人群和現實環境中的表現，並為標籤和上市後監測提供資訊。醫療保健提供者使用 RWE 來確定針對特定患者群體的最有效的治療方法，以支援根據個人需求量身定做治療的個人化醫療方法。付款人和保險公司利用 RWE 來評估治療的成本效益、指導報銷決策並確保將資源分配給提供最大價值的治療。 RWE 的主要好處包括透過深入了解醫療產品的真實有效性和安全性來治療患者、支持以證據為基礎的決策以及根據真實患者體驗告知治療策略，其中包括改進的能力。

推動現實世界證據解決方案市場成長的因素有哪些？

現實世界證據解決方案市場的成長受到多種因素的推動。隨著醫療保健相關人員尋求基於確鑿證據做出明智決策，對基於價值的醫學的日益重視以及證明醫療產品在現實世界中的有效性的需求是一個主要的促進因素。資料分析、人工智慧和數位健康平台的技術進步也透過增加 RWE 解決方案的功能和可訪問性來推動市場成長。對個人化醫療的需求不斷成長，以及支援監管核准的資料需求，特別是對於罕見和複雜的疾病，進一步推動了對 RWE 的需求。此外，電子病歷、穿戴式裝置和病患報告結果的採用正在增加數位健康資料的可用性，擴大 RWE 調查的範圍和規模。這些因素，加上製藥公司、醫療保健提供者和監管機構之間日益加強的合作，正在推動現實世界證據解決方案市場的持續成長。

受訪的公司範例（所有 46 家有興趣的公司）

  • Aetion
  • Cognizant Technology Solutions US Corporation
  • IBM Corporation
  • Ignite Data Limited
  • IQVIA
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • Pharmaceutical Product Development LLC
  • SAS Institute, Inc.
  • Syneos Health

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP14362

Global Real World Evidence Solutions Market to Reach US$4.4 Billion by 2030

The global market for Real World Evidence Solutions estimated at US$1.7 Billion in the year 2023, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 14.3% over the analysis period 2023-2030. Real World Evidence Services, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Real World Evidence Data Sets segment is estimated at 12.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$460.9 Million While China is Forecast to Grow at 13.3% CAGR

The Real World Evidence Solutions market in the U.S. is estimated at US$460.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$652.6 Million by the year 2030 trailing a CAGR of 13.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Real World Evidence Solutions Market - Key Trends and Drivers Summarized

Real World Evidence Solutions: Transforming Healthcare with Data-Driven Insights

Real World Evidence (RWE) solutions are transforming healthcare by providing data-driven insights that enhance decision-making across the industry. RWE refers to the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD). This data is collected from various sources, including electronic health records (EHRs), claims databases, patient registries, and wearable devices. RWE is increasingly being used by pharmaceutical companies, regulators, and healthcare providers to inform drug development, regulatory approvals, and patient care strategies. Unlike traditional clinical trials, which are conducted under controlled conditions, RWE provides insights into how treatments perform in everyday clinical settings, offering a more comprehensive understanding of a product’s effectiveness and safety. This approach is becoming essential for demonstrating the value of new therapies, especially in personalized medicine and for rare diseases.

What Technological Advancements Are Enhancing the Collection and Utilization of RWE?

Technological advancements are significantly enhancing the collection, analysis, and utilization of RWE, making it a more powerful tool for healthcare stakeholders. The integration of big data analytics, artificial intelligence (AI), and machine learning (ML) into RWE platforms allows for the processing of vast amounts of RWD, uncovering patterns and insights that would be impossible to detect manually. Advances in data integration technologies are also enabling the aggregation of data from diverse sources, creating comprehensive datasets that provide a holistic view of patient outcomes. Moreover, the use of natural language processing (NLP) is improving the extraction of meaningful data from unstructured sources, such as physician notes and social media. These technological innovations are not only improving the quality and accuracy of RWE but are also making it more accessible and actionable for decision-makers in healthcare.

What Are the Key Applications and Benefits of RWE in Healthcare?

RWE is used in a wide range of applications in healthcare, offering significant benefits that enhance patient outcomes, improve healthcare efficiency, and support regulatory decision-making. In drug development, RWE is used to supplement clinical trial data, providing insights into how a drug performs across different populations and in real-world settings, which can inform labeling and post-market surveillance. Healthcare providers use RWE to identify the most effective treatments for specific patient populations, supporting personalized medicine approaches that tailor care to individual needs. Payers and insurers leverage RWE to assess the cost-effectiveness of treatments, guiding reimbursement decisions and ensuring that resources are allocated to therapies that offer the greatest value. The primary benefits of RWE include its ability to provide insights into the real-world effectiveness and safety of medical products, support evidence-based decision-making, and improve patient care by informing treatment strategies based on actual patient experiences.

What Factors Are Driving the Growth in the Real World Evidence Solutions Market?

The growth in the Real World Evidence Solutions market is driven by several factors. The increasing emphasis on value-based care and the need to demonstrate the real-world effectiveness of medical products are significant drivers, as healthcare stakeholders seek to make informed decisions based on robust evidence. Technological advancements in data analytics, AI, and digital health platforms are also propelling market growth by enhancing the capabilities and accessibility of RWE solutions. The rising demand for personalized medicine and the need for data to support regulatory approvals, particularly for rare diseases and complex conditions, are further boosting demand for RWE. Additionally, the growing availability of digital health data, driven by the adoption of EHRs, wearable devices, and patient-reported outcomes, is expanding the scope and scale of RWE studies. These factors, combined with increasing collaboration between pharmaceutical companies, healthcare providers, and regulatory bodies, are driving the sustained growth of the Real World Evidence Solutions market.

Select Competitors (Total 46 Featured) -

  • Aetion
  • Cognizant Technology Solutions U.S. Corporation
  • IBM Corporation
  • Ignite Data Limited
  • IQVIA
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • Pharmaceutical Product Development LLC
  • SAS Institute, Inc.
  • Syneos Health

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Real World Evidence Solutions - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Evidence-Based Healthcare Propels Market Growth
    • Technological Advancements in Data Integration and Analytics Strengthen Market Position
    • Growing Focus on Personalized Medicine and Patient-Centric Care Drives Adoption of Real World Evidence Solutions
    • Surge in Demand for Post-Market Surveillance and Safety Monitoring Generates New Opportunities
    • Development of Advanced Data Collection and Management Platforms Sustains Market Growth
    • Expanding Applications in Drug Development and Clinical Trials Throws Spotlight on Market Potential
    • Rising Adoption of Real World Evidence in Payer Decision-Making and Reimbursement Processes Propels Market Expansion
    • Surge in Demand for Real-Time Data and Predictive Analytics Expands Market Horizons
    • Growing Awareness of the Benefits of Real World Evidence in Enhancing Treatment Outcomes Drives Market Adoption
    • Innovations in Artificial Intelligence and Machine Learning Generate New Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Real World Evidence Solutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Data Sets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Data Sets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Healthcare Payers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Healthcare Payers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Healthcare Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Healthcare Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 13: World Real World Evidence Solutions Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical & Medical Devices Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Pharmaceutical & Medical Devices Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 16: USA Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: USA 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 18: USA Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Canada 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • JAPAN
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Japan 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • CHINA
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 28: China Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: China 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 30: China Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: China 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • EUROPE
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe 7-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Europe 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Europe 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • FRANCE
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 40: France Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: France 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • GERMANY
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Germany 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • ITALY
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Italy 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Italy 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • UNITED KINGDOM
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 52: UK Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: UK 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Rest of World 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Rest of World 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030

IV. COMPETITION